AG˹ٷ

STOCK TITAN

[Form 4] Clearwater Analytics Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for KORU Medical Systems, Inc. (KRMD) discloses that director Shahriar Matin acquired 4,189 shares of common stock on 07/02/2025 at a reported price of $3.58 per share. Following the transaction, Matin’s direct ownership increased to 87,604 shares. No derivative security activity or additional explanatory notes beyond the standard boiler-plate language were provided. The filing was signed by Attorney-in-Fact Thomas Adams.

La presentazione del Modulo 4 per KORU Medical Systems, Inc. (KRMD) rivela che il direttore Shahriar Matin ha acquistato 4.189 azioni ordinarie il 02/07/2025 a un prezzo riportato di 3,58 $ per azione. Dopo la transazione, la proprietà diretta di Matin è aumentata a 87.604 azioni. Non sono state fornite attività su titoli derivati né note esplicative aggiuntive oltre al linguaggio standard previsto. La presentazione è stata firmata dall’Avvocato Delegato Thomas Adams.

La presentación del Formulario 4 de KORU Medical Systems, Inc. (KRMD) revela que el director Shahriar Matin ܾó 4,189 acciones ordinarias el 02/07/2025 a un precio reportado de $3.58 por acción. Tras la transacción, la propiedad directa de Matin aumentó a 87,604 acciones. No se proporcionó actividad con valores derivados ni notas explicativas adicionales más allá del lenguaje estándar. La presentación fue firmada por el Apoderado Thomas Adams.

KORU Medical Systems, Inc. (KRMD)� Form 4 제출� 따르� 이사 Shahriar Matin2025� 7� 2�� 보통� 4,189�� 주당 $3.58� 취득했습니다. 거래 � Matin� 직접 소유 주식은 87,604�� 증가했습니다. 파생증권 거래 내역이나 표준 문구 � 추가 설명은 제공되지 않았습니�. � 제출 서류� 대리인 Thomas Adams 변호사가 서명했습니다.

Le dépôt du Formulaire 4 pour KORU Medical Systems, Inc. (KRMD) révèle que le directeur Shahriar Matin a acquis 4 189 actions ordinaires le 02/07/2025 à un prix déclaré de 3,58 $ par action. Suite à cette transaction, la détention directe de Matin a augmenté à 87 604 actions. Aucune activité sur titres dérivés ni notes explicatives supplémentaires au-delà du langage standard n’ont été fournies. Le dépôt a été signé par le mandataire Thomas Adams.

Die Einreichung des Formulars 4 für KORU Medical Systems, Inc. (KRMD) zeigt, dass Direktor Shahriar Matin am 02.07.2025 4.189 Aktien des Stammkapitals zu einem gemeldeten Preis von 3,58 $ pro Aktie erworben hat. Nach der Transaktion stieg Matins Direktbesitz auf 87.604 Aktien. Es wurden keine Aktivitäten mit derivativen Wertpapieren oder zusätzliche erläuternde Hinweise über die übliche Standardformulierung hinaus bereitgestellt. Die Einreichung wurde vom Bevollmächtigten Thomas Adams unterzeichnet.

Positive
  • Director insider purchase adds 4,189 shares, signalling personal confidence in KRMD’s prospects.
Negative
  • None.

Insights

TL;DR: Minor insider purchase; bullish signal but immaterial in size.

This Form 4 shows a director adding roughly $15,000 worth of stock (4,189 × $3.58). While insider buying is directionally positive—indicating personal confidence—the volume represents a small fraction of both trading liquidity and total shares outstanding, so the market impact should be limited. No derivative grants or sales were reported, suggesting the transaction is straightforward equity accumulation.

La presentazione del Modulo 4 per KORU Medical Systems, Inc. (KRMD) rivela che il direttore Shahriar Matin ha acquistato 4.189 azioni ordinarie il 02/07/2025 a un prezzo riportato di 3,58 $ per azione. Dopo la transazione, la proprietà diretta di Matin è aumentata a 87.604 azioni. Non sono state fornite attività su titoli derivati né note esplicative aggiuntive oltre al linguaggio standard previsto. La presentazione è stata firmata dall’Avvocato Delegato Thomas Adams.

La presentación del Formulario 4 de KORU Medical Systems, Inc. (KRMD) revela que el director Shahriar Matin ܾó 4,189 acciones ordinarias el 02/07/2025 a un precio reportado de $3.58 por acción. Tras la transacción, la propiedad directa de Matin aumentó a 87,604 acciones. No se proporcionó actividad con valores derivados ni notas explicativas adicionales más allá del lenguaje estándar. La presentación fue firmada por el Apoderado Thomas Adams.

KORU Medical Systems, Inc. (KRMD)� Form 4 제출� 따르� 이사 Shahriar Matin2025� 7� 2�� 보통� 4,189�� 주당 $3.58� 취득했습니다. 거래 � Matin� 직접 소유 주식은 87,604�� 증가했습니다. 파생증권 거래 내역이나 표준 문구 � 추가 설명은 제공되지 않았습니�. � 제출 서류� 대리인 Thomas Adams 변호사가 서명했습니다.

Le dépôt du Formulaire 4 pour KORU Medical Systems, Inc. (KRMD) révèle que le directeur Shahriar Matin a acquis 4 189 actions ordinaires le 02/07/2025 à un prix déclaré de 3,58 $ par action. Suite à cette transaction, la détention directe de Matin a augmenté à 87 604 actions. Aucune activité sur titres dérivés ni notes explicatives supplémentaires au-delà du langage standard n’ont été fournies. Le dépôt a été signé par le mandataire Thomas Adams.

Die Einreichung des Formulars 4 für KORU Medical Systems, Inc. (KRMD) zeigt, dass Direktor Shahriar Matin am 02.07.2025 4.189 Aktien des Stammkapitals zu einem gemeldeten Preis von 3,58 $ pro Aktie erworben hat. Nach der Transaktion stieg Matins Direktbesitz auf 87.604 Aktien. Es wurden keine Aktivitäten mit derivativen Wertpapieren oder zusätzliche erläuternde Hinweise über die übliche Standardformulierung hinaus bereitgestellt. Die Einreichung wurde vom Bevollmächtigten Thomas Adams unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Erickson Scott Stanley

(Last) (First) (Middle)
C/O CLEARWATER ANALYTICS HOLDINGS, INC.
777 W. MAIN STREET, SUITE 900

(Street)
BOISE ID 83702

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Clearwater Analytics Holdings, Inc. [ CWAN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Revenue Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/30/2025 M 3,125(1) A $0.00 15,079 D
Class A Common Stock 06/30/2025 M 5,157(1) A $0.00 20,236 D
Class A Common Stock 06/30/2025 S 2,777(2) D $21.6732 17,459 D
Class A Common Stock 06/30/2025 S 1,683(2) D $21.6732 15,776 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0.00 06/30/2025 M 3,125 (3) 02/28/2034 Class A Common Stock 3,125 $0.00 31,250 D
Restricted Stock Unit $0.00 06/30/2025 M 5,157 (4) 02/13/2035 Class A Common Stock 5,157 $0.00 72,187 D
Explanation of Responses:
1. These shares represent shares acquired upon the vesting of Restricted Stock Units ("RSUs").
2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
3. 6.25% of the Restricted Stock Units shall vest at the end of each 3-month period for the next 4 years following January 1, 2024, and will settle within thirty days of the applicable vesting date.
4. 6.25% of the Restricted Stock Units shall vest at the end of each 3-month period for the next 4 years following January 1, 2025, and will settle within thirty days of the applicable vesting date.
Remarks:
/s/ Alphonse Valbrune, as Attorney-in-Fact, for Scott Erickson 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KRMD's Form 4 dated 07/02/2025 report?

Director Shahriar Matin acquired 4,189 KRMD common shares at $3.58 each.

How many KRMD shares does the director now own?

Post-transaction, Matin holds 87,604 shares directly.

Were any derivative securities involved in this filing?

No. Table II shows no derivative activity for the reporting person.

Is the transaction coded as a purchase or sale?

Table I lists the transaction as an "A" acquisition of common stock.

Who signed the Form 4 on behalf of the insider?

The filing was signed by Thomas Adams, Attorney-in-Fact for Shahriar Matin.
Clearwater Analytics Hldgs Inc

NYSE:CWAN

CWAN Rankings

CWAN Latest News

CWAN Latest SEC Filings

CWAN Stock Data

5.89B
256.50M
1.12%
104.99%
2.89%
Software - Application
Services-prepackaged Software
United States
BOISE